Oxaliplatin intravenous

DRUG2 trials

Sponsors

Federation Francophone de Cancerologie Digestive

Conditions

Colorectal NeoplasmsMetastatic Colorectal Carcinoma (mCRC)

Phase 2

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

Not yet recruitingNCT07150403

Federation Francophone de Cancerologie DigestiveMetastatic Colorectal Carcinoma (mCRC)

Start: 2025-12-31End: 2028-10-31Target: 74Updated: 2025-09-08

Phase 3

Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

RecruitingNCT02885753

Federation Francophone de Cancerologie DigestiveColorectal Neoplasms

Start: 2016-12-31End: 2028-09-30Target: 348Updated: 2025-07-09

Related Papers

Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49.

2022-01-115 citations

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study.

2020-06-0818 citations